Related Experiment Video
Updated: May 7, 2026

Sample Preparation to Bioinformatics Analysis of DNA Methylation: Association Strategy for Obesity and Related Trait Studies
Published on: May 6, 2022
Interface between pharmacotherapy and genes in human obesity
Annalouise O'Connor1, Andrew G Swick
1UNC Chapel Hill Nutrition Research Institute, Kannapolis, N.C., USA.
Abstract:
Obesity is a polygenic chronic condition, and dysregulation in multiple underlying energy balance processes drives the obese phenotype. Lifestyle changes can be difficult to sustain long term, and anti-obesity drugs can be an advantageous component of a successful weight loss plan. However, due to lack of efficacy or adverse safety profiles, there is currently a limited selection of anti-obesity drugs on the market. This, coupled with the notable interindividual variability in efficacy of approved treatments, represents a significant unmet medical need. In this review, we will highlight this variability in weight loss response to these existing anti-obesity compounds and discuss how underpinning genetic variation is associated with weight loss outcomes. Existing research in the field of pharmacogenomics and obesity drugs will be highlighted, as will possibilities for future focus. We will conclude by exploring examples of successful pharmacogenomics studies, and also by asking how pharmacogenomics can be built into the drug development pipeline for the benefit of patients and pharmaceutical companies alike.
Insights
Genetic variations influence how individuals respond to anti-obesity drugs. Understanding this pharmacogenomics can improve weight loss success and drug development for obesity.
Area of Science:
- Pharmacogenomics
- Obesity Research
- Drug Development
Background:
- Obesity is a complex polygenic condition with limited effective long-term treatments.
- Current anti-obesity medications have variable efficacy and safety profiles, creating an unmet medical need.
- Interindividual variability in treatment response necessitates personalized approaches.
Purpose of the Study:
- To review the variability in weight loss response to existing anti-obesity drugs.
- To discuss the association between genetic variation and weight loss outcomes.
- To explore the role of pharmacogenomics in optimizing obesity pharmacotherapy and drug development.
Main Methods:
- Literature review of existing anti-obesity compounds and their efficacy.
- Analysis of pharmacogenomic studies linking genetic variations to weight loss.
- Exploration of successful pharmacogenomics case studies.
Main Results:
- Significant interindividual variability exists in the efficacy of current anti-obesity drugs.
- Genetic factors are associated with differing weight loss outcomes among patients.
- Pharmacogenomics offers a pathway to predict and enhance treatment response.
Conclusions:
- Personalizing anti-obesity medication based on genetic profiles can improve patient outcomes.
- Integrating pharmacogenomics into drug development pipelines can lead to more effective obesity treatments.
- Further research is needed to fully leverage pharmacogenomics for obesity management.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Metabolism: Overview
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
